Microbial hydroxylation of 2-cycloalkylbenzoxazoles. Part I. Product spectrum obtained from Cunninghamella blakesleeana DSM 1906 and Bacillus megaterium DSM 32
摘要:
2-Cycloalkyl-1, 3-benzoxazoles and -thiazoles (ring sizes C-3 to C-8) were biotransformed using the title microorganisms. Products of preparative importance were (1S, 3S)-3-(benz-1, 3-oxazol-2-yl)cyclopentan-1-ol 6, (1R)-3-(benz-1, 3-oxazol-2-yl)cyclopentan-1-one 8, (1R, 2R)-2-(benz-1, 3-oxazol-2-yl)cyclohexan-1-ol 14 and the corresponding cycloheptanol and cycloheptanone derivatives.
Microbial hydroxylation of 2-cycloalkylbenoxazoles. Part II. Determination of product structures and enhancement of enantiomeric excess
摘要:
The determinations of product structures obtained in the microbial hydroxylations of various 2-cycloalkyl-1, 3-benzoxazoles using Cunninghamella blakesleeana DSM 1906 and Bacillus megaterium DSM 32 are described. The initially low e.e. of 3-(benz-1, 3-oxazol-2-yl)cyclopentan-1-ol 6, 2-(benz-1, 3-oxazol-2-yl)cyclohexan-1-ol 14 and 4-(2-bent-1, 3-oxazol-2-yl)cycloheptan-1-ol 21 can be enhanced to 98% using lipase catalyzed resolution.
BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE
申请人:Piramal Life Sciences Limited
公开号:EP2077846A2
公开(公告)日:2009-07-15
[EN] BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] COMPOSÉS DE BENZOXAZÉPINE, LEUR PRÉPARATION ET LEUR UTILISATION
申请人:NICHOLAS PIRAMAL INDIA LTD
公开号:WO2008053446A2
公开(公告)日:2008-05-08
[EN] The invention provides a novel benzoxazepine compound of the general formula (I): wherein R1 and R2 are as defined in the specification; or a stereoisomer, a geometric isomer, a a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a polymorph thereof; a process for its preparation; and a pharmaceutical composition including an effective amount of the compound. The compounds are useful in the treatment of insulin resistance and clinical conditions associated therewith. [FR] L'invention concerne un nouveau composé de benzoxazépine répondant à la formule générate (I) : dans laquelle R1 et R2 sont tels que définis dans la spécification ; ou un stéréoisomère, un isomère géométrique, un sel pharmaceutiquement acceptable, un solvate pharmaceutiquement acceptable, ou un polymorphe de celui-ci ; un procédé pour sa préparation ; et une composition pharmaceutique comprenant une quantité efficace du composé. Le composé est utile dans le traitement de la résistance à l'insuline et des états cliniques associés.